Sanofi Sees No Opening to Actelion Talks After J&J Re-Entry

Sanofi Sees No Opening to Actelion Talks After J&J Re-Entry


Sanofi doesn't see an opening to make a deal with Actelion Ltd. while the Swiss target is in acquisition talks with U.S. drug giant Johnson & Johnson, said Elias Zerhouni, the French drugmaker's global research and development president. "There is an exclusive relationship right now with J&J," Zerhouni said Monday during an interview with Bloomberg Television's Erik Schatzker at the J.P. Morgan Healthcare Conference in San Francisco.



from Biotech News